康体生命成立于2016年，为国家高新技术企业，为客户提供包括GPCR等靶点蛋白纳米抗体药物开发CRO服务。公司由长江学者杜洋教授领衔，技术团队由多位生物医药博士负责，组建有哺乳动物细胞、昆虫细胞、酵母、大肠杆菌等蛋白表达纯化平台，纳米抗体发现平台，抗体工程平台，质量分析平台等，为客户提供纳米抗体定制研发解决方案。康体生命拥有2000平米实验室及各种实验设备。纳米抗体开发团队免疫或筛选过的抗原或靶点包括但不限于Hpv16，Hpv18，Claudin18.2，Lilrb-2，Amyloid A，Procalcitonin，TAC2，PD-1，PD-L1，CTLA4，CD3（epsilon&gamma），Integrin，病毒样颗粒，AAV，IL-5.PCSK9，KLH偶联的各种多肽包括磷酸化多肽及乙酰化或甲基化多肽，KLH-HAKLH-Myc,KLH-Flag,GST,CD7,CD28,CD33,CD38,CD70,CD73,CD79,CD22,CD123,CD167, GRP78，Human RAGE，HSP70，HSP90，ROR1，IGF2R，IGFBP5，GPC3，SARS-CoV-2 S1包括Delta及Omicron RBD蛋白，EBV gHqL，KRAS，CXCL1，GUCY2C，hTPX2，Nectin4，Leptin，FGF R4,VEGFR2,VEGFR3,FAP,CEACAM5,PSMA,PSA,YAP,B7H7,TIGIT,VEGF A,IL-2R,Wnt2, 人载脂蛋白A-1，人载脂蛋白 B， 人血红蛋白，SERPINA3，人转铁蛋白，GFP.mCherry，鼠lgG，兔lgG及许多客户提供的不知名的靶点蛋白。除了蛋白抗原外，康体生命科技有限公司也用细胞，灭活病毒，病毒样颗粒，细胞膜碎片等对羊驼进行免疫。
AlpaLife is a biotechnology company in China founded by scientists with strong background in antibody production and G-protein coupled receptors (GPCRs) drug discovery. Now we exclusively engage in development and production of customized well-performed and high-quality Alpaca nanobodies (single-domain antibodies or VHHs) for cytoplasmic proteins and membrane proteins (especially GPCRs) and related products for life-sciences, biotechnology and bio-medical research.
Nanobodies are the emerging novel tools for both basic scientific research and clinical therapeutics. They have unique properties including small size (~15 KD), high affinity, excellent solubility, superior stability, quick clearance from blood, and deep tissue penetration, which enables a wide range of applications such as affinity capture reagents, crystallization chaperones, target imaging and immunomodulation, biosensors, in vivo imaging, antivenom therapy and anti-infective agents.
AlpaLife carries out nanobodies development through both Immune and non-Immune naïve and synthetic libraries. We have been working with multiple top pharmaceutical companies in China. Cooperated with laboratories in more than ten countries including U.S., Germany, South Korea, Thailand etc. Trying to provide the products with the best service, quality and reliability to the scientific community worldwide. Now we already have successful cases including human C-Reactive Protein nanobodies and 2019-Sars-Cov2 spike protein nanobodies, and we are collaborating with the Chinese University of Hong Kong in Shen Zhen for GPCR targeted nanobodies development.
We offer one-stop solution from antigen preparation to selected nanobody purification and evolution. With extensive experience in custom single domain antibody development, we are ready to help simplify and accelerate your research by novel nanobodies.